How big is the trigeminal neuralgia treatment market today, and what are its future growth expectations?
The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.68 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing incidence of chronic diseases, increasing prevalence of neurological disorders, increasing prevalence of trigeminal neuralgia, growing demand for minimally invasive treatments, and rising demand for minimally invasive surgeries.
The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing awareness of trigeminal neuralgia among healthcare professionals and the general population, an increase in TN cases, a rising geriatric population, increasing healthcare expenditure, and an increase in the number of diagnosed cases. Major trends in the forecast period include advancements in neuromodulation techniques, advancements in TENS technology, advancements in medical research and technology, adoption of minimally invasive surgical techniques, and digital health technologies.
Get Your Free Sample of The Global Trigeminal Neuralgia Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21307&type=smp
What have been the primary factors driving the trigeminal neuralgia treatment market’s growth?
The rising prevalence of neurological disorders is expected to propel the growth of the trigeminal neuralgia treatment market going forward. Neurological disorders refer to any conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. The increasing prevalence of neurological disorders can be attributed to various factors, including genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Trigeminal neuralgia treatment supports neurological patients by relieving severe facial pain, reducing nerve irritation, enhancing quality of life, helping manage pain, and preventing further neurological harm. For instance, in April 2022, according to the European Brain Council, a Belgium-based non-profit organization, over 600 neurological diseases and nearly 300 psychiatric conditions afflict millions globally, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Therefore, the rising prevalence of neurological disorders is expected to drive the growth of the trigeminal neuralgia treatment market.
What are the key segments within the trigeminal neuralgia treatment market?
The trigeminal neuralgia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants
2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy
3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy
Order your report now for swift delivery
Which key players are shaping the trigeminal neuralgia treatment market?
Major companies operating in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.
How will emerging trends drive the trigeminal neuralgia treatment market throughout the forecast period?
Major companies operating in the trigeminal neuralgia treatment market are focusing on new drug (IND) applications to ultimately gain regulatory approval and expand their market share. An investigational new drug (IND) application is the process by which a pharmaceutical company requests approval from regulatory agencies to start testing a new drug in humans, aiming to assess its safety, effectiveness, and appropriate dosage. For instance, in February 2022, Noema Pharma, a Switzerland-based clinical-stage biotechnology company received an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), a US-based government agency for LibraTN to initiate a Phase 2b clincial trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN is a 24-week, multi-center, placebo-controlled study to assess the efficacy and safety of NOE-101 in adults with TN-related pain and is expected to report in the first half of 2024. The Food and Drug Administration) (FDA) also granted fast track designation to basimglurant (NOE-101) to expedite the development and review of the drug.
How do regional factors impact the trigeminal neuralgia treatment market, and which region is the largest contributor?
North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Trigeminal Neuralgia Treatment Market Report 2025 Offer?
The trigeminal neuralgia treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Trigeminal neuralgia treatment involves medical strategies to manage the severe, sharp facial pain caused by trigeminal neuralgia, which affects the trigeminal nerve. The main goal of trigeminal neuralgia treatment is to alleviate pain, reduce the frequency and intensity of episodes, and address the underlying nerve irritation, ultimately enhancing the patient’s quality of life.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21307
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
